A dynamic force in the fight against infectious diseases

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens.

Learn More

A ground-breaking advancement

Fungerps: our novel anti-fungal agents

The fungerps are an innovative new weapon for potential deployment against a range of serious fungal infections.

Learn More

Innovation in action

Life-Threatening Infections

We’re bringing new weapons to the fight against debilitating and life-threatening infections that pose serious challenges in hospitals.

Learn More

Serving Unmet Needs

Anti-microbial resistance threat

The increase of antifungal-resistant pathogens is reported globally. Considering the limited treatment options and often deadly outcomes of these diseases, antifungal resistance is a significant global health threat.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 03/31/26

    SCYNEXIS Announces $40.0 Million Private Placement

    Read More >
  • 03/31/26

    SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Read More >
  • 03/04/26

    SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

    Read More >
  • 02/26/26

    SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

    Read More >
  • 01/28/26

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    Read More >
  • 01/21/26

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    Read More >
  • 12/22/25

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    Read More >
  • 11/19/25

    SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

    Read More >
  • 11/17/25

    Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

    Read More >
  • 11/05/25

    SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease.

Learn More